AI ECG vs. Clinical Reality: Resolving Diagnostic Discordance

AI in ECG interpretation is here, and it’s creating a common headache for cardiologists. What do you do when an AI-enabled ECG flags a patient for silent left ventricular dysfunction, but the follow-up echo comes back negative? Clinicians are now stuck between a highly sensitive screening tool and the traditional workup, trying to make sense of discordant signals. This Q&A gets into a practical protocol for handling these mismatches, figuring out how to balance the AI alert with what you see on standard imaging.

Working through the AI-ECG Dilemma: A Clinician’s Perspective

It’s a situation we’re all seeing more of: an AI-ECG algorithm, often cleared through the FDA’s 510(k) pathway, flags an asymptomatic patient for a high probability of low ejection fraction (LEF). Then the echocardiogram, our gold standard for checking EF, shows normal systolic function. This discordance forces you to weigh a predictive algorithm against the hard certainty of an image. The real issue is that these two tools are measuring different things, and we’ve got to figure out how to put those signals together into a single clinical picture. The FDA’s framework for these AI/ML-driven medical devices (SaMD, specifically) rightly pushes for strong clinical validation, and for a device to get a 510(k) clearance, its manufacturer has to show it’s substantially equivalent to an existing device. The problem is that AI’s ability to detect subtle patterns of silent disease often goes beyond what older tech could do, which is where real-world evidence (RWE) comes in to supplement the key trials and build a stronger case for both FDA submissions and payer acceptance.

The Pioneering Work of Dr. Paul Friedman and Mayo Clinic

A lot of what we know about using AI-ECG for silent heart conditions comes directly from the research of Dr. Paul Friedman’s team at Mayo Clinic. They’ve done the deep work on how well these algorithms can spot patients with low ejection fraction who don’t have any symptoms, with major studies published in journals like Nature Medicine that show impressive sensitivity and specificity. Nature Medicine study on AI-ECG for low ejection fraction A key takeaway from their research is that AI-ECG is a screening tool, not a replacement for an echo. Its job is to find at-risk people who would otherwise fly completely under the radar. The AI is picking up on tiny electrical patterns in the ECG that correlate with structural and functional heart changes, often before a patient feels anything or an echo can see a clear problem. That’s why you get the so-called ‘false positive’ when the follow-up echo is normal. It’s likely pointing to a subclinical state or a predisposition that our current imaging just can’t capture yet. This work, moving from academic validation to a real-world product, is what led Mayo Clinic to license its AI-ECG technology to Anumana. This is a good example of the path from a validated academic concept to a commercial tool, with Anumana getting its own FDA 510(k) clearance for its low ejection fraction ECG-AI in October 2023. FDA 510(k) summary for Anumana ECG-AI These clearances are what build trust, making sure the tools have clinical guardrails and an oversight model to catch errors before they affect a patient.

A Structured Protocol for Managing Discordant AI-ECG Signals

So, what do you do with a positive AI-ECG for LEF but a negative workup? You need a structured, evidence-based plan. This protocol combines the AI’s signal with our traditional diagnostics to keep patients safe and get to the right outcome:

1. Re-evaluate the Clinical Context: Go back to the chart. Look again at the patient’s full history, their risk factors for heart failure (e.g., hypertension, diabetes, coronary artery disease), and ask about subtle symptoms like mild exertional dyspnea that might’ve been missed.
2. Verify AI-ECG Interpretation: Confirm the AI-ECG was performed and interpreted correctly. It’s rare with validated systems, but tech glitches or user error can happen. You need to know the specific sensitivity and specificity of the algorithm you’re using for low ejection fraction, since that context is everything for interpreting the result.
3. Consider Repeat Echocardiography or Advanced Imaging: If the first echo was a while back or the read was a bit ambiguous, think about repeating it. For select patients where your clinical suspicion is still high despite a normal echo, an advanced tool like cardiac MRI (CMR) can give a much more detailed picture of structure and function, sometimes picking up things an echo misses.
4. Biomarker Assessment: Check cardiac biomarkers like N-terminal pro-B-type natriuretic peptide (NT-proBNP). If the levels are up, even with a normal echo, that strengthens the case that the AI is onto something, suggesting myocardial stress that warrants closer follow-up.
5. Serial Surveillance and Watchful Waiting: For an asymptomatic patient with a positive AI-ECG and a definitively clean initial workup, ‘watchful waiting’ is often a good strategy. This means regular clinic visits, repeat AI-ECG screenings, and maybe another echo in 6-12 months. This respects the AI’s predictive ability for early or subclinical disease, letting you intervene quickly if the condition progresses.
6. Patient Education and Shared Decision-Making: Clinicians need to be transparent with the patient about the AI-ECG finding, what the subsequent workup showed, and the plan for surveillance. It helps to explain that the AI is a very sensitive screening tool that can pick up early signals, even before other tests can confirm them. This builds trust and keeps the patient engaged in their own care.

The point of a protocol like this is to treat an AI-ECG alert for silent disease as a reason for a more systematic investigation, not something to just dismiss because of one normal imaging study. They should trigger a thorough look, using the AI to identify patients who need closer attention. The goal is to integrate the AI’s predictive insights into a complete, patient-centered diagnostic strategy.

The Role of Peer Review and Clinical Validation

Bringing any AI tool from a lab concept to the clinic hinges on tough peer review and a ton of clinical validation. Dr. Friedman’s work at Mayo Clinic is the model for this, with his team’s studies having to pass muster with the scientific community before being accepted. That’s how we establish that an AI algorithm is clinically reliable and will perform as expected across different patient populations. For these tools to become part of our daily practice, they must be built on real patient training data, have peer-reviewed outcome validation, operate within defined clinical guardrails, and include an oversight model that can catch errors. This is what gives clinicians confidence and ensures the technology enhances, not complicates, patient care. The FDA’s evolving guidance on AI/ML medical devices, including frameworks like the Predetermined Change Control Plan (PCCP), helps create a solid regulatory path for these adaptive technologies, letting manufacturers make pre-planned updates without a whole new submission every time. FDA guidance on AI/ML-based SaMD

Conclusion

Dealing with a mismatch between an AI-ECG interpretation and the clinical picture means you have to understand what the AI can and can’t do. Using a structured diagnostic protocol allows cardiologists to effectively use the predictive strength of AI while sticking to established clinical standards. The combination of foundational research from places like Mayo Clinic, clear regulatory pathways from the FDA, and a real commitment to peer-reviewed validation is what will allow us to integrate clinically solid AI into cardiovascular care, leading to earlier detection and improved patient outcomes.